<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589784</url>
  </required_header>
  <id_info>
    <org_study_id>07-135</org_study_id>
    <nct_id>NCT00589784</nct_id>
    <nct_alias>NCT00561665</nct_alias>
  </id_info>
  <brief_title>Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma</brief_title>
  <official_title>Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out what effects, good and/or bad, sunitinib has on
      patients and their tumors. At this time, no drugs are routinely used to treat meningioma,
      hemangioblastoma or hemangiopericytoma. Only surgery and radiation therapy are known to be
      useful.

      Sunitinib is a drug approved for advanced kidney cancer. Sunitinib is also being studied for
      other tumors. It may be useful in the treatment of brain tumors because it can prevent
      formation of new blood vessels that allow tumor cells to survive and grow.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II study of Sunitinib in patients with recurrent or inoperable meningiomas.
      An exploratory study will be performed for patients with recurrent hemangiopericytoma or
      hemangioblastoma. There will be approximately 50 patients enrolled on this study (40
      meningiomas and 10 hemangiopericytomas/hemangioblastomas). The treatment plan is to use daily
      SU11248 at a dose of 50 mg, using the established schedule of 4 weeks of treatment followed
      by two weeks of rest period, forming a six-week treatment cycle. A medical professional will
      see each patient at least every six weeks while on the medication for toxicity assessment and
      physical examination. Extent of disease evaluations will occur at baseline, two weeks, twelve
      weeks, 24 weeks, and every twelve weeks thereafter. These evaluations will include MRI of the
      brain (or CT head if a patient cannot undergo MRI) and MR perfusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Objective Response</measure>
    <time_frame>1.5 years</time_frame>
    <description>Determine the overall objective response</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>CNS Cancer</condition>
  <condition>Meningioma</condition>
  <condition>Intracranial Hemangiopericytoma</condition>
  <condition>Hemangioblastoma</condition>
  <condition>Neurofibromatosis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks, followed by a two-week rest period. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Imaging studies will be performed after every other cycle. Patients may continue on study as long as they are tolerating treatment and in the absence of disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Patients on strong CYP3A4 inducers should start at a dose of 62.5 mg and those</other_name>
    <other_name>on strong CYP3A4 inhibitors should start at a dose of 37.5 mg. The dose should</other_name>
    <other_name>be taken once daily at approximately the same time each day.</other_name>
    <other_name>Patients are required to have a drug rest period of at least 14 days after</other_name>
    <other_name>each dosing period. The start of the next cycle may be delayed if additional</other_name>
    <other_name>time is required for the patient to recover from sunitinib-associated toxicity</other_name>
    <other_name>experienced during the previous cycle. An interruption in therapy of greater</other_name>
    <other_name>than 28 days must be approved by the PI. Dosing can be modified after</other_name>
    <other_name>discussion with the study investigator. The study investigator may implement</other_name>
    <other_name>dose suspension or reduction in order to ensure patient safety. Patients will</other_name>
    <other_name>be given a diary to take home to record their sunitinib dosing.</other_name>
    <other_name>This will be brought back to the clinic following each cycle of treatment.</other_name>
    <other_name>SU011248</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven recurrent meningioma or intracranial hemangiopericytoma or
             hemangioblastoma. This includes benign, atypical, or malignant meningioma; patients
             with neurofibromatosis type 1 or 2 may participate.

          -  Patients with classic radiographic picture of meningioma may also enroll if not
             surgically accessible. In this instance the patient must be reviewed at
             multi-disciplinary brain tumor conference including neurosurgery and neuroradiology to
             determine that the patient is appropriate for this study.

          -  Unequivocal evidence for tumor progression by MRI (or CT scan if MRI is
             contraindicated). The scan must be performed within 14 days of registration.

          -  Steroids dosing - malignant meningiomas must be on stable dose for at least 5 days
             prior to baseline imaging. For patients with benign or atypical meningiomas, stable
             steroid doses are not required.

          -  Recent resection for recurrent tumor - patients will be eligible as long as they have
             recovered from the effects of surgery and have residual disease that can be evaluated.
             To best assess the extent of residual disease post-operatively, a CT/MRI should be
             done no later than 96 hours in the immediate post-operative period or at least 4 weeks
             post-operatively. If the 96 hour scan is more than 14 days before registration, it
             should be repeated. Because Sunitinib is a VEGF inhibitor that can carry many risks
             including thrombocytopenia, bleeding, hypertension, and stroke, patients must wait at
             least 14 days after surgery, without complication, before they may initiate study
             drug.

          -  Prior radiation therapy - patients may have been treated with standard external beam
             radiation, interstitial brachytherapy, or radiosurgery in any combination. An interval
             of ≥ 4 weeks (28 days) must have elapsed from the completion of radiation therapy to
             study entry and there must be subsequent evidence of tumor progression. Patients with
             prior interstitial brachytherapy or stereotactic radiosurgery must have confirmation
             of true progressive disease rather than radiation necrosis based on PET, MR
             spectroscopy or surgical documentation of disease.

          -  Patients who have not had prior surgery or radiotherapy for their meningioma will be
             reviewed at multi-disciplinary brain tumor conference including neurosurgery and
             radiation oncology to determine that the patient is appropriate for this study.

          -  Prior therapy: There is no limitation on the number of prior surgeries, radiation
             therapy, radiosurgery treatments, or chemotherapy.

          -  All patients must sign an informed consent indicating that they are aware of the
             investigational nature of the study. Patients must sign an authorization for the
             release of their protected health information.

          -  Age ≥ 18 years old

          -  Karnofsky performance status ≥ 60%.

          -  ≥ 4 weeks since prior RT, stereotactic radiosurgery, or chemotherapy.

          -  Required Initial Laboratory Values (within 14 days of registration):

        Absolute neutrophil count (ANC) ≥ 1,000/mm3

          -  Platelets ≥ 100,000/mm3

          -  hemoglobin ≥ 8gm/dl

          -  Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and
             serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 x
             local laboratory upper limit of normal (ULN)

          -  Creatinine ≤ 2.0 mg/dl

          -  PT, INR, and PTT ≤ 1.5 times institutional upper limits of normal

          -  Total serum bilirubin ≤ 1.5 - Patients with a history of NF may have other stable CNS
             tumors, such as schwannoma, acoustic neuroma, or ependymoma, but ONLY if these lesions
             have been stable in size for the preceding 6 months.

        Exclusion Criteria:

          -  Patients with the history of any other cancer (except non-melanoma skin cancer or
             carcinoma in-situ of the cervix, unless in complete remission and off all therapy for
             the disease for a minimum of 3 years) are ineligible.

          -  Any prior TKI therapy (SU011248, Sorafenib, Semaxinib, Axitinib)

          -  Concomitant use of any other investigational drugs

          -  Concomitant use of enzyme-inducing anti-epileptic drugs.

          -  Concomitant use of St John's Wort.

          -  Any of the following within the 6 months prior to study drug administration:
             myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass
             graft, symptomatic congestive heart failure, cerebrovascular accident or transient
             ischemic attack, or pulmonary embolism.

          -  Ongoing cardiac dysrhythmias of NCI CTCAE Version 3.0 grade ≥ 2.

          -  Prolonged QTc interval on baseline EKG (&gt;450 msec for males and &gt;470 msec for
             females).

          -  Uncontrolled hypertension (&gt;150/100 mm Hg despite optimal medical therapy). Patients
             are excluded if they have an elevated diastolic, an elevated systolic, or both.

          -  History of intracranial hemorrhage.

          -  Pre-existing thyroid abnormality, with thyroid function tests that cannot be
             maintained in the normal range with medication.

          -  Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
             (AIDS)-related illness or other active infection.

          -  Concurrent treatment on another clinical trial. Supportive care trials or
             non-treatment trials, e.g. QOL, are allowed.

          -  Ongoing treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg
             daily for thromboembolic prophylaxis is allowed).

          -  Pregnancy or breast-feeding. Patients must be surgically sterile, postmenopausal, or
             agree to use effective contraception during the period of therapy. The definition of
             effective contraception will be based on the judgment of the principal investigator or
             a designated associate. Male patients must be surgically sterile or agree to use
             effective contraception. Women of childbearing potential must have a negative B-HCG
             pregnancy test documented within 14 days prior to registration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Kaley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center at Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health Science Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan-Kettering web site</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <results_first_submitted>December 21, 2015</results_first_submitted>
  <results_first_submitted_qc>December 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 25, 2016</results_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sunitinib</keyword>
  <keyword>Brain Cancer</keyword>
  <keyword>CNS Cancer</keyword>
  <keyword>meningioma</keyword>
  <keyword>intracranial hemangiopericytoma</keyword>
  <keyword>hemangioblastoma</keyword>
  <keyword>malignant meningioma</keyword>
  <keyword>neurofibromatosis</keyword>
  <keyword>neurofibromatosis type 1</keyword>
  <keyword>neurofibromatosis type 2</keyword>
  <keyword>07-135</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Hemangiopericytoma</mesh_term>
    <mesh_term>Hemangioblastoma</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Cytochrome P-450 CYP3A Inducers</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aggressive Memingioma</title>
          <description>Patients with Aggressive Memingioma</description>
        </group>
        <group group_id="P2">
          <title>Exploratory Cohort</title>
          <description>Patients with WHO grade I meningioma, HPC and hemangioblastoma</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient inevaluable</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aggressive Memingioma</title>
          <description>Patients with Aggressive Memingioma</description>
        </group>
        <group group_id="B2">
          <title>Exploratory Cohort</title>
          <description>Patients with WHO grade I meningioma, HPC and hemangioblastoma</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Median Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="27" upper_limit="85"/>
                    <measurement group_id="B2" value="48" lower_limit="32" upper_limit="79"/>
                    <measurement group_id="B3" value="59" lower_limit="27" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Objective Response</title>
        <description>Determine the overall objective response</description>
        <time_frame>1.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aggressive Memingioma</title>
            <description>Patients with Aggressive Memingioma</description>
          </group>
          <group group_id="O2">
            <title>Exploratory Cohort</title>
            <description>Patients with WHO grade I meningioma, HPC and hemangioblastoma</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Objective Response</title>
          <description>Determine the overall objective response</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression of Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>All patients treated with Sunitinib (SU011248)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lueukopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Prolonged QTc Interval</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Right Ventricular Enlargement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS Hemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombic Microangiopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Thrombosis/ Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash, Hand-Foot Reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash, Hand-Foot Reaction</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Thomas Kaley</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>212-639-5122</phone>
      <email>KaleyT@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

